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Hydrophobically modified magnetic nanoparticles 
(MNPs) were encapsulated within the membrane of 
poly(trimethylene carbonate)-b-poly(L-glutamic 
acid) (PTMC-b-PGA) block copolymer vesicles 
using a nanoprecipitation process. This formulation 
method provides a high loading of MNPs (up to 70 
wt %) together with a good control over the sizes of 
the vesicles (100 – 400 nm). The deformation of the 
vesicle membrane under an applied magnetic field 
was evidenced by anisotropic SANS. These hybrid 
objects display contrast enhancement properties in 
Magnetic Resonance Imaging, a diagnostic method 
routinely used for three-dimensional and non-
invasive scans of the human body.1 They can also 
be guided in a magnetic field gradient. The 
feasibility of drug release triggered by magnetic 
induction was evidenced using the anticancer drug 
doxorubicin (DOX), which is co-encapsulated in 
the membrane. Magnetic polymersomes are thus 
proposed as multimodal drug nanocarriers for bio-
imaging and magneto-chemotherapy. 
In the new field of nanomedicine, a great variety of 
polymeric drug delivery nanocarriers have shown 
efficient entrapment and controlled release of drugs 
in vitro. However, evaluating the fate of the carrier 
after injection in vivo is a delicate task: as a 
consequence, an imaging probe is usually co-
encapsulated with the drugs in the polymer 
nanoparticles. Such multifunctional nanocarriers for 
cancer diagnostics and treatment open the field of 
“theranostics”, i.e. combination of imaging and 
therapeutic functions in “all-in-one” nanoparticles.2 
Among the different nanoparticles used in 
biotechnological applications, superparamagnetic 
nanocrystals made of γ-Fe2O3 around 10 nm in size 
are of particular interest since they are 
biocompatible and offer contrast enhancement in 
MRI. In addition, MNPs can also be implemented 
to induce cancer cells apoptosis. Local heating is 
obtained by exposure to radio-frequency magnetic 
fields in the frequency range 100 kHz – 1MHz, due 
to thermal dissipation by the magnetic moments 
forced to oscillate at the frequency of the applied 
magnetic field. Hyperthermia therapy (i.e. treating 
by heat) has been recognized as a promising form 
of cancer therapy, particularly in synergy with 
chemo- or radio-therapy.3 For a solid tumor located 
not too deep under the skin (such as melanoma), a 
conventional hyperthermia treatment is applied, the 
cancer cells being destroyed by the heat shock. We 
proposed a totally different strategy with a polymer 
vesicle delivering a drug through the temperature 
increase induced by radiofrequency magnetic fields 
not macroscopically but locally, at the scale of the 
membrane: the MNPs being confined inside the 
polymer block, the heat dissipates in the vicinity of 
the polymer membrane, which strongly impacts its 
permeability. Therefore we called this strategy 
“magneto-chemotherapy” as depicted on Fig. 1.4 
 
 
 
Fig. 1: Dually-loaded vesicles prepared by addition at 
controlled speed of an aqueous buffer into a mixture in 
DMSO of PTMC-b-PGA (m=19 and n=24), doxorucin 
and magnetic nanoparticles coated by the BEY surfactant 
of given formula (bottom sketch). The cryo-TEM image 
(top right panel) shows a vesicle wrapped by a mantle of 
MNPs, which excitation by a RF magnetic field heats up 
the membrane locally and accelerates the DOX release. 
In this highlight paper, we describe a convenient 
way to prepare fully biodegradable polymersomes 
featuring a dual magnetic and thermo-responsive 
membrane. The hydrophobic core of membranes is 
made of the PTMC semi-crystalline blocks and the 
hydrophilic leaflets arise from the PGA polypeptide 
blocks of the copolymer. One pot nanoprecipitation 
(Fig. 1) leads to dual-loaded vesicles with iron 
oxide MNPs of appropriate size and coating (BEY) 
embedded within the membranes together with the 
antitumor drug doxorubicin. The amphiphilic 
diblock copolymer was synthesized by ring-
opening polymerization of γ-benzyl-L-glutamate N-
carboxyanhydride initiated by amino functionalized 
PTMC macroinitiator upon a previously published 
method.5 PTMC24-b-PGA19 presents a hydrophilic 
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weight fraction of 50 wt % for an overall molar 
mass Mn = 4900 g/mol with a dispersity index 1.15. 
On the other hand, magnetic iron oxides MNPs 
were synthesized in water by alkaline co-
precipitation of ferrous and ferric salts followed by 
coating with a surfactant called Beycostat (bottom 
sketch on Fig 1). The gyration and hydrodynamic 
radii of these MNPs were respectively 
RGMNP=3.05±0.06 nm and RHMNP=4.70±0.07 nm as 
measured by SANS and DLS.   
Nanoprecipitation allowed reaching quantitative 
loading contents (LC) with controlled final sizes 
and low polydispersity indexes, as reported on this 
table for two durations of the buffer addition (PBS 
pH=7.4), with and without DOX. 
The two-dimensional confinement of the MNPs 
inside the vesicular membranes was evidenced by 
small angle neutron and light scattering techniques 
and observed by transmission electron microscopy. 
The magnetic membranes exhibited a reversible 
deformation under a permanent magnetic field of 
moderate intensity (0.1 Tesla) as seen on Fig. 2. 
 
 
Fig. 2 Top: SANS patterns of magnetic vesicles loaded at 
50 wt. % MNPs in H2O in the q range 3×10-3 – 3×10-2 Å-1 
at zero field and under B=0.1 Tesla. Colors correspond to 
iso-intensity ranges. Patterns were averaged in angular 
sectors (-30° 30°) along the field direction or (-15° 15°) 
around the perpendicular direction. Bottom: Kratky-
Porod fits Ln[q2 I(q)] ~ - q2 δ2 /12 in the low q regime 
lead to membrane thicknesses in the two directions δ// 
and δ┴ and to a scheme of the overall deformation. 
With pure H2O as solvent, the nuclear scattering of 
the inorganic component of membranes was much 
greater than that of the polymer leaflets. Thus a 
variation in intensity in both directions can be 
ascribed to a reorganization of the MNPs within the 
membrane. The variation of δ// and δ┴ as a function 
of the field intensity is interpreted by the stretching 
of the membrane near the magnetic poles due to an 
overall deformation of the vesicle into an elongated 
ellipsoid. The apparent increase of thickness near 
the equator and concomitant decrease near the 
magnetic poles (δ┴ = 18 nm, δ// = 8 nm at B=0.6 T) 
indicates that MNPs move away from the poles 
where dipolar repulsions are strong and accumulate 
in the other portions of membrane where dipolar 
interactions are expected to be attractive 
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Fig. 3: In vitro release assays of doxorubicin at two 
temperatures (23 or 37°C) and with or without an applied 
radio-frequency magnetic field B=2.65 mT at 500 kHz. 
Finally, the release of the anticancer drug was 
assayed under several heating conditions. A global 
heating at 37°C (melting temperature of PTMC6) 
caused a significantly higher release than the one 
observed at 23°C, as explained by a more 
permeable membrane. But the application of an 
oscillating magnetic field at 23°C induced 
hyperthermia at a local (nanometric) scale only in 
the vicinity of the membrane that provoked an 
increase in DOX release (by 2 times), thereby 
evidencing the validity of the concept of magneto-
chemotherapy with those magnetic polymersomes. 
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Addition 
time 
MNP 
LC 
DOX 
LC 
RH 
(nm) PDI 
ζ 
(mV) 
15 min 35 % 
0 % 152 0.15 -39.6 
12 % 124 0.23 -39.3 
10 sec 50 % 
0 % 56.5 0.22 -40.8 
9 % 61 0.15 -42.0 
